Targeting Delivery of IL-15 to PD-L1 Expressing Tumors With An Anti- PD-L1 IgM Antibody
Time: 9:00 am
Details:
- IGM-7354 is an anti-PD-L1 pentameric high affinity, high avidity IgM engineered with an IL-15 fused to the joining chain designed to deliver IL-15 to PD-L1 expressing tumors to enhance anti-tumor immune responses
- Properties include more potent PD-L1 binding and blockade of PD-1 than an IgG antibody, potent proliferation of NK, CD8+ T cells, reversal of T cell exhaustion, dose-dependent cytotoxicity of cancer cells in vitro, and additivity and/or potential synergy with antibodies mediating ADCC.
- In vivo, IGM-7354 dose-dependently increased circulating NK and CD8+ T cells which correlated with tumor regressions. IGM-7354 was well tolerated in cynomolgus monkeys and dose dependently induced the proliferation of peripheral NK, CD8+ and γδ T cells.